This study elucidates the immunogenic landscape of these rare bladder cancer subtypes, laying the groundwork for future trials using antibodies that are currently in clinical development to expand therapeutic options by including TIM-3, TIGIT, and LAG-3 into the immunomodulatory armamentarium. This evidence concerns the gene HAVCR2 and urinary bladder carcinoma.